Nurix Therapeutics Inc Aktie News

Presentation of preclinical data from novel IRAK4 protein degrader, GS-6791, discovered in Nurix's ongoing research collaboration with Gilead Sciences

Nurix Therapeutics, Inc. (NASDAQ:NRIX ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with our next firesid...

Nurix Therapeutics, Inc. (NASDAQ:NRIX ) Baird Global Healthcare Conference 2025 September 9, 2025 10:50 AM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participants Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Presentation Brian Skorney Senior Research Analyst Good morning, everyone.

Nurix Therapeutics, Inc. (NASDAQ:NRIX ) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 1:30 PM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participants Robert Burns - H.C.

Nurix Therapeutics, Inc. (NASDAQ:NRIX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:00 AM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst All right. Great. Good morning.

SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, Hans van Houte, chief financial officer, John Northcott, chief commerci...

NRIX's Bexobrutideg shows impressive ORR for refractory CLL/WM. I believe this positions it as a potential best-in-class BTK degrader in a sizable TAM. Nurix Therapeutics also works with other big pharma like Gilead, Sanofi, and Pfizer to expand its promising targeted protein degradation IP franchise. I estimate their cash and marketable securities provide roughly 1.9 years of cash runway based...

Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM)